Here are the 10-K annual reports from PURE Bioscience (PURE) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PURE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PURE filings page.
PURE Bioscience reported fiscal 2026 net product sales of $2.315 million, versus $2.198 million in fiscal 2025; the $117,000 increase was attributed to higher sales across its end-user network serving food processing. Gross margin was 57%, compared with 59%; selling, general and administrative expense was $3.077 million versus $3.259 million, and research and development expense was $332,000 versus $316,000. The company recorded a $2.483 million net loss and used $1.738 million of cash in operating activities in fiscal 2026.
At July 31, 2026, cash and cash equivalents were $569,000 compared with $334,000 as of July 31, 2025; total liabilities were $7.592 million, and stockholders’ deficiency was $6.399 million. As of July 31, 2026, convertible notes payable of $1.015 million were past due. PURE said these conditions raise substantial doubt about its ability to continue as a going concern within one year after the report date. On February 13, 2026, it issued convertible notes with an aggregate principal balance of $970,000 under its fiscal 2026 note purchase agreement.
PURE Bioscience, Inc. filed its annual report for the year ended July 31, 2025. The company reported net product sales of $2.20 million, up from $1.96 million in 2024, and a net loss of $2.4 million versus a $3.4 million loss last year. Cash was $334,000 as of July 31, 2025, and auditors expressed substantial doubt about the company’s ability to continue as a going concern.
The business focuses on proprietary silver dihydrogen citrate (SDC) antimicrobial products, including PURE Hard Surface (EPA-registered) and PURE Control (FDA Food Contact Notifications for poultry and produce). Customer concentration remains notable; the largest customer represented 18% of net product sales in 2025. As of October 29, 2025, there were 111,886,473 shares outstanding. The company completed a private placement of convertible debt with $2.0 million in net proceeds during fiscal 2025 and indicates the need for additional capital to fund operations.
PURE continues to pursue food-safety markets through distributors and partnerships while navigating extensive regulatory requirements from the EPA, FDA, USDA and foreign authorities.